keyword
MENU ▼
Read by QxMD icon Read
search

mRcc

keyword
https://www.readbyqxmd.com/read/28548948/effect-of-renal-embolization-in-patients-with-synchronous-metastatic-renal-cell-carcinoma-a-retrospective-comparison-of-cytoreductive-nephrectomy-and-systemic-medical-therapy
#1
Sung Han Kim, Jung Kwon Kim, Boram Park, Jungnam Joo, Jae Young Joung, Ho Kyung Seo, Kang Hyun Lee, Jinsoo Chung
OBJECTIVE: To compare survival outcomes for renal embolization (RE) to cytoreductive nephrectomy (CN) and no primary renal treatment (NT) among patients with synchronous metastatic renal cell carcinoma (mRCC) treated using either targeted therapy (TT) or immunotherapy (IT). RESULTS: The median follow-up duration was 81.3 months, with a duration of first-line treatment of 3.5 months. Among the 211 patients, the median PFS and OS were 4.4 and 10.6 months. Specifically for patients receiving TT (124 patients), the PFS and OS were 5...
May 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28546463/a-phase-ii-study-of-everolimus-plus-oral-prednisone-in-patients-with-metastatic-renal-cell-cancer
#2
Cristian Lolli, Valentina Gallà, Giuseppe Schepisi, Domenico Barone, Salvatore Luca Burgio, Antonio Maugeri, Bernadette Vertogen, Dino Amadori, Ugo De Giorgi
LESSONS LEARNED: The combination of everolimus and low-dose prednisone administered daily was hypothesized to prevent noninfectious pneumonitis (NIP) and mucositis, two common adverse events related to everolimus. Although mucositis was detected in only one case, all-grade NIP occurred in four of eight cases (50%), and this was considered enough to stop accrual of the study.These data suggest the need for careful monitoring of patients receiving everolimus who are treated with corticosteroids...
May 25, 2017: Oncologist
https://www.readbyqxmd.com/read/28545466/preoperative-cholesterol-level-as-a-new-independent-predictive-factor-of-survival-in-patients-with-metastatic-renal-cell-carcinoma-treated-with-cyto-reductive-nephrectomy
#3
Hakmin Lee, Yong June Kim, Eu Chang Hwang, Seok Ho Kang, Sung-Hoo Hong, Jinsoo Chung, Tae Gyun Kwon, Cheol Kwak, Hyeon Hoe Kim, Jong Jin Oh, Sang Chul Lee, Sung Kyu Hong, Sang Eun Lee, Seok-Soo Byun
BACKGROUND: The obesity and lipid metabolism were previously proposed to be related with the clinical outcomes of metastatic renal cell carcinoma (mRCC). We tried to investigate the relationship between preoperative cholesterol level (PCL) and survival outcomes in patients with mRCC. METHODS: We analysed the data of 244 patients initially treated with cyto-reductive nephrectomy after being diagnosed with mRCC. Patients were stratified into two groups according to the PCL cut-off level of 170 mg/dL...
May 25, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28535693/experience-with-sunitinib-in-metastatic-renal-cell-carcinoma-mrcc-patients-pooled-analysis-from-3-spanish-observational-prospective-studies
#4
Daniel Castellano, José Pablo Maroto, Enrique Espinosa, Enrique Grande, Victoria Bolos, Julia Linares, Emilio Esteban, Aranzazu Gonzalez Del Alba, M A Climent, J A Arranz, Mª José Méndez, Eva Fernadez Parra, Luis Antón-Aparicio, Cristina Bayona, Isabel Gallegos, Enrique Gallardo, Luz Samaniego, J Garcia Donas
BACKGROUND: A pivotal, randomized, phase III trial demonstrated a statistically significant superiority of sunitinib over interferon-α in metastatic renal cell carcinoma (mRCC) patients. OBJECTIVE: To evaluate the effectiveness and safety of sunitinib in patients with advanced or mRCC in routine clinical practice. METHODS: Retrospective pooled analysis of clinical data from three observational and prospective studies carried out between 2007 and 2011 in 33 Spanish hospitals...
May 24, 2017: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/28532444/haemoglobin-level-increase-as-an-efficacy-biomarker-during-axitinib-treatment-for-metastatic-renal-cell-carcinoma-a-retrospective-study
#5
Alison C Johnson, Margarida Matias, Helen Boyle, Bernard Escudier, Alicia Molinier, Brigitte Laguerre, Carole Helissey, Pierre-Emmanuel Brachet, Audrey Emmanuelle Dugué, Loic Mourey, Elodie Coquan, Florence Joly
BACKGROUND: Axitinib is used after failure of first line treatment for metastatic renal cell carcinoma (mRCC). A known side effect is the increase of haemoglobin level (HbL) during treatment with a suspected correlation with better outcome. Our objective was to examine whether HbL increase during the first three months of axitinib treatment is associated with better prognosis. METHODS: Retrospective multicentre analysis including patients with mRCC treated with axitinib for at least three months from 2012 to 2014...
May 22, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28531203/potential-health-gains-for-patients-with-metastatic-renal-cell-carcinoma-in-daily-clinical-practice-a-real-world-cost-effectiveness-analysis-of-sequential-first-and-second-line-treatments
#6
S De Groot, H M Blommestein, W K Redekop, S Sleijfer, L A L M Kiemeney, E Oosterwijk, C A Uyl-de Groot
INTRODUCTION: Randomised controlled trials have shown that targeted therapies like sunitinib are effective in metastatic renal cell carcinoma (mRCC). Little is known about the current use of these therapies, and their associated costs and effects in daily clinical practice. We estimated the real-world cost-effectiveness of different treatment strategies comprising one or more sequentially administered drugs. METHODS: Analyses were performed using patient-level data from a Dutch population-based registry including patients diagnosed with primary mRCC from January 2008 to December 2010 (i...
2017: PloS One
https://www.readbyqxmd.com/read/28523933/the-pazoreal-noninterventional-study-to-assess-effectiveness-and-safety-of-pazopanib-and-everolimus-in-the-changing-metastatic-renal-cell-carcinoma-treatment-landscape
#7
Peter J Goebell, Christian Doehn, Carsten Grüllich, Viktor Grünwald, Thomas Steiner, Rainer Ehneß, Manfred Welslau
VEGFR and mTOR inhibitors are broadly used in metastatic renal cell carcinoma (mRCC) therapy, and sequential first-line pazopanib (VEGFR inhibitor) and second-line everolimus (mTOR inhibitor) is a standard treatment option. Nivolumab and lenvatinib/everolimus combination was recently approved in Europe for use in mRCC after previous therapy. Prospective routine data on sequential therapy including nivolumab and/or lenvatinib are missing. This is a prospective, noninterventional study, which evaluates the effectiveness, tolerability, safety and quality of life following 450 patients with mRCC starting either on pazopanib as first-line therapy or third-line everolimus plus/minus lenvatinib following nivolumab...
May 19, 2017: Future Oncology
https://www.readbyqxmd.com/read/28521783/association-of-post-treatment-hypoalbuminemia-and-survival-in-chinese-patients-with-metastatic-renal-cell-carcinoma
#8
Wen Cai, Jin Zhang, Yonghui Chen, Wen Kong, Yiran Huang, Jiwei Huang, Lixin Zhou
BACKGROUND: Hypoalbuminemia adversely affects the clinical outcomes of various cancers. The purpose of this study was to estimate the prognostic value of hypoalbuminemia 3-5 weeks after treatment in patients with metastatic renal cell carcinoma (mRCC) who received sorafenib or sunitinib as first-line treatment. METHODS: In this single-center, retrospective study, we assessed the progression-free survival (PFS) and overall survival (OS) of 184 mRCC patients who received first-line sorafenib or sunitinib treatment...
May 18, 2017: Chinese Journal of Cancer
https://www.readbyqxmd.com/read/28515811/first-line-sunitinib-or-pazopanib-in-metastatic-renal-cell-carcinoma-the-canadian-experience
#9
Aly-Khan A Lalani, Haocheng Li, Daniel Y C Heng, Lori Wood, Austin Kalirai, Georg A Bjarnason, Hao-Wen Sim, Christian K Kollmannsberger, Anil Kapoor, Sebastien J Hotte, Marie Vanhuyse, Piotr Czaykowski, M Neil Reaume, Denis Soulieres, Peter Venner, Scott North, Naveen S Basappa
INTRODUCTION: Clinical trial data has shown pazopanib to be non-inferior in overall survival (OS) compared to sunitinib as first-line treatment for metastatic renal cell carcinoma (mRCC). The purpose of this study was to evaluate outcomes and compare dose-modifying toxicities of mRCC patients treated with suntinib or pazopanib in the real-world setting. METHODS: Data were collected on mRCC patients using the prospective Canadian Kidney Cancer Information System (CKCis) database from January 2011 to November 2015...
March 2017: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/28511146/real-world-prospective-experience-of-axitinib-in-metastatic-renal-cell-carcinoma%C3%A2-in-a-large-comprehensive-cancer-centre
#10
Margarida Matias, Gwénaël Le Teuff, Laurence Albiges, Annalisa Guida, Caroline Brard, Giulia Bacciarelo, Yohann Loriot, Christophe Massard, Nathalie Lassau, Karim Fizazi, Bernard Escudier
BACKGROUND: Axitinib has shown activity in metastatic renal cell carcinoma (mRCC) in a large phase III clinical trial and was approved in patients who failed first-line therapy. This drug has been available in France since November 2012. The objective is to report efficacy and safety of axitinib in mRCC outside of clinical trials. METHODS: A prospective evaluation of mRCC patients treated by axitinib in second or further next-line therapy at Gustave Roussy was conducted from 2012 to 2015...
May 13, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28504837/immunotherapy-for-metastatic-renal-cell-carcinoma
#11
REVIEW
Susanne Unverzagt, Ines Moldenhauer, Monika Nothacker, Dorothea Roßmeißl, Andreas V Hadjinicolaou, Frank Peinemann, Francesco Greco, Barbara Seliger
BACKGROUND: Since the mid-2000s, the field of metastatic renal cell carcinoma (mRCC) has experienced a paradigm shift from non-specific therapy with broad-acting cytokines to specific regimens, which directly target the cancer, the tumour microenvironment, or both.Current guidelines recommend targeted therapies with agents such as sunitinib, pazopanib or temsirolimus (for people with poor prognosis) as the standard of care for first-line treatment of people with mRCC and mention non-specific cytokines as an alternative option for selected patients...
May 15, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28503236/impact-of-neutrophil-to-lymphocyte-ratio-on-effects-of-targeted-therapy-for-metastatic-renal-cell-carcinoma-patients-with-extrapulmonary-metastasis
#12
Jun Teishima, Shinya Ohara, Kousuke Sadahide, Shinsuke Fujii, Hiroyuki Kitano, Kohei Kobatake, Shunsuke Shinmei, Keisuke Hieda, Shogo Inoue, Tetsutaro Hayashi, Koji Mita, Akio Matsubara
INTRODUCTION: The aim of our present study was to investigate the impact of the pretreatment neutrophil-to-lymphocyte ratio (NLR) on the antitumour effects of targeted agents in patients with metastatic renal cell carcinoma (mRCC). METHODS: The NLRs in 283 cases of molecular targeted therapy for mRCC were measured before starting the prescription of the molecular targeted agent. The significance of pretreatment NLR on the site of metastatic organs and on progression-free survival (PFS) in each case was analyzed...
May 2017: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/28503232/cytoreductive-nephrectomy-in-the-modern-era-predictors-of-use-morbidity-and-survival
#13
Brian J Minnillo, William Tabayoyong, John J Francis, Matthew J Maurice, Hui Zhu, Simon Kim, Robert Abouassaly
INTRODUCTION: To determine tumour, patient, and provider factors associated with cytoreductive nephrectomy (CN) use and to identify those factors that predicted short-term and long-term surgical outcomes. METHODS: We performed a retrospective review (1998-2011) of the National Cancer Database, a U.S. population-based oncology outcomes database. The review included 36 549 patients with metastatic renal cell carcinoma (mRCC). We assessed predictors of CN use, length of stay (LOS), 30-day readmission, and 30-day mortality using multivariable logistic regression...
May 2017: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/28495053/evaluation-of-preoperative-aspartate-transaminase-alanine-transaminase-ratio-as-an-independent-predictive-biomarker-in-patients-with-metastatic-renal-cell-carcinoma-undergoing-cytoreductive-nephrectomy-a%C3%A2-propensity-score-matching-study
#14
Hiroki Ishihara, Tsunenori Kondo, Kazuhiko Yoshida, Kenji Omae, Toshio Takagi, Junpei Iizuka, Kazunari Tanabe
BACKGROUND: The usefulness of the aspartate transaminase (AST)/alanine transaminase (ALT) ratio (De Ritis ratio) as a predictive biomarker for patients with metastatic renal cell carcinoma (mRCC) undergoing cytoreductive nephrectomy (CN) remains unclear. PATIENTS AND METHODS: The data from 118 patients were retrospectively evaluated. The endpoints were cancer-specific survival (CSS) and overall survival (OS) after CN. We compared these according to the AST/ALT ratio before and after 1:1 propensity score matching...
April 20, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28492158/metachronous-metastatic-renal-cell-carcinoma-to-the-jejunum-presenting-with-massive-lower-gastrointestinal-bleeding
#15
Reem Al- Salamah, Hamad Hadi Al- Qahtani, Jaber Ali Alfaifi, Saleh Al- Harbi
Metastatic renal cell carcinoma (MRCC) is a rare cause of massive lower gastrointestinal bleeding (LGIB). We report a 51-year man who underwent left nephrectomy for renal cell carcinoma (RCC) 6 years ago. presenting with massive LGIB. Preoperative abdominal computed tomography (CT) revealed small bowel mass. Exploration of the abdomen revealed jejunal mass. Resection of the mass along with the jejunal segment with end-to-end anastomosis was performed. Histopathology of the jejunal mass confirmed MRCC. MRCC should be expected as a source of massive LGIB in a patient with history of RCC...
April 2017: Journal of the College of Physicians and Surgeons—Pakistan: JCPSP
https://www.readbyqxmd.com/read/28485356/patterns-of-care-and-outcomes-for-second-line-targeted-therapy-in-metastatic-renal-cell-carcinomas-a-registry-based-analysis
#16
S Zanwar, A Joshi, V Noronha, V M Patil, N Sable, P Popat, S Menon, R Kothari, P Bhargava, A Kapoor, K Prabhash
AIM: Patterns of care for metastatic renal cell carcinomas (mRCC) have seen tremendous reform in the last decade. Here, we present our pattern of care in second-line targeted therapy for mRCC. METHODS: Patients with mRCC treated with second-line therapy were included from a prospective database. Demographics, risk stratification, and treatment details were noted. Event-free survival (EFS) and overall survival (OS) was calculated using Kaplan-Meier method. Log-rank test was used to identify factors affecting EFS and OS...
October 2016: Indian Journal of Cancer
https://www.readbyqxmd.com/read/28485355/initial-experience-with-first-line-pazopanib-in-the-treatment-of-metastatic-renal-cell-carcinoma-a-single-institution-data
#17
A Joshi, V Agarwala, A Ramaswamy, V Noronha, V M Patil, S Menon, P Popat, N Sable, K Prabhash
INTRODUCTION: Pazopanib is one of the recently introduced first-line therapeutic options in the treatment of metastatic renal cell carcinoma (mRCC). There is no published literature from India on the use of pazopanib in mRCC. MATERIALS AND METHODS: We report the efficacy and toxicity analysis of first-line pazopanib therapy administered for patients with mRCC at our institute. It is a retrospective analysis of a prospectively maintained continuous data. RESULTS: Between March 2013 and December 2015, 28 patients have been treated with pazopanib...
October 2016: Indian Journal of Cancer
https://www.readbyqxmd.com/read/28448047/a-syngeneic-mouse-model-of-metastatic-renal-cell-carcinoma-for-quantitative-and-longitudinal-assessment-of-preclinical-therapies
#18
Katherine A Murphy, Britnie R James, Andrew Wilber, Thomas S Griffith
Renal cell carcinoma (RCC) affects > 60,000 people in the United States annually, and ~ 30% of RCC patients have multiple metastases at the time of diagnosis. Metastatic RCC (mRCC) is incurable, with a median survival time of only 18 months. Immune-based interventions (e.g., interferon (IFN) and interleukin (IL)-2) induce durable responses in a fraction of mRCC patients, and multikinase inhibitors (e.g., sunitinib or sorafenib) or anti-VEGF receptor monoclonal antibodies (mAb) are largely palliative, as complete remissions are rare...
April 12, 2017: Journal of Visualized Experiments: JoVE
https://www.readbyqxmd.com/read/28442891/spotlight-on-nivolumab-in-the-treatment-of-renal-cell-carcinoma-design-development-and-place-in-therapy
#19
REVIEW
Vyshak Alva Venur, Monika Joshi, Kenneth G Nepple, Yousef Zakharia
Several tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptors and molecules inhibiting the mammalian target of rapamycin are being used for management of metastatic renal cell carcinoma (mRCC); however, there is still a potential for improvement. Immune checkpoint inhibitors like nivolumab and other PD-1/PD-L1 inhibitors provide an alternative approach for patients with mRCC. In this article, the authors review the safety profile and outcomes of phase 1, 2, and 3 clinical trials of nivolumab in mRCC...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28439491/translating-new-data-to-the-daily-practice-in-second-line-treatment-of-renal-cell-carcinoma-the-role-of-tumor-growth-rate
#20
EDITORIAL
Enrique Grande, Olga Martínez-Sáez, Pablo Gajate-Borau, Teresa Alonso-Gordoa
The therapeutic options for patients with metastatic renal cell carcinoma (mRCC) have completely changed during the last ten years. With the sequential use of targeted therapies, median overall survival has increased in daily practice and now it is not uncommon to see patients surviving kidney cancer for more than four to five years. Once treatment fails with the first line targeted therapy, head to head comparisons have shown that cabozantinib, nivolumab and the combination of lenvatinib plus everolimus are more effective than everolimus alone and that axitinib is more active than sorafenib...
April 10, 2017: World Journal of Clinical Oncology
keyword
keyword
77808
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"